zabilugene almadenorepvec

AXP000008.2 · Oncolytic virus

Platform
adenovirus (Ad5, RGD-modified capsid, E2F-responsive E1A)
Originator
VCN Biosciences
Sponsor
Theriva Biologics

Names

NameTypeSource
zabilugene almadenorepvecpreferred name, INNcurator, ncit
VCN-01codencit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (VCN-01)
Replication
conditionally replicating
Modifications
E2F-responsive E1A with Delta-24; RGD-modified fiber; replaced E1A Sp1 sites
Transgenes
SPAM1
Route
intravenous, intratumoral, intravitreal
Source
evidence

Cross-references

NCI Thesaurus
C211709
FDA UNII
3HBM7CA87P

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07701486A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingPhase 1/22026-07-312027-08-016Ductal Adenocarcinoma of the Pancreas; Pancreas Cancer, Metastatic; Pancreas Cancer, Stage IV
NCT05673811Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerCompletedPhase 22023-01-102025-03-28112Metastatic; Pancreatic Adenocarcinoma
NCT05057715huCART-meso + VCN-01 in Pancreatic and Ovarian CancerTerminatedPhase 12022-03-022026-04-2913Pancreatic Cancer; Serous Ovarian Cancer
NCT03799744Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell CarcinomaUnknownPhase 12019-03-202023-01-3120Carcinoma, Squamous Cell of Head and Neck; Head and Neck Neoplasms; Metastasis; Recurrence
NCT03284268Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory RetinoblastomaCompleted2017-09-062024-06-1413Retinoblastoma, Recurrent
NCT02045602Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid TumorsCompletedPhase 12014-012019-0542Locally Advanced Solid Tumors; Metastatic Solid Tumors; Pancreatic Adenocarcinoma
NCT02045589A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic CancerCompletedPhase 12014-012016-108Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42257887Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research2026name in title: VCN-01
PMID 42816596Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.Nature medicine2026cited by trial NCT05673811
PMID 35338084Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.Journal for immunotherapy of cancer2022cited by trial NCT02045602
PMID 35149591VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.Journal for immunotherapy of cancer2021cited by trial NCT02045589
PMID 30674657Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.Science translational medicine2019name in title: VCN-01

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40880319Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.Human gene therapy2025name in title: VCN-01
PMID 31591461The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models.Scientific reports2019name in title: VCN-01
PMID 26603261The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research2016name in title: VCN-01
PMID 26808201Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.PloS one2016name in title: VCN-01
PMID 27280773Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.PloS one2016name in title: VCN-01
PMID 25391696Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.Clinical cancer research : an official journal of the American Association for Cancer Research2015name in title: VCN-01
Unconfirmed matches (3)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: VCN-01
PMID 34377767Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation.Molecular therapy oncolytics2021name in abstract: VCN-01
PMID 30497448Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET.BMC cancer2018name in abstract: VCN-01

Notes

Transgene is human PH20 hyaluronidase; HGNC symbol for PH20 is SPAM1 (curator mapping). VCN Biosciences spun out of ICO-IDIBELL and was acquired by Synthetic Biologics in 2022, which renamed itself Theriva Biologics. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

zabilugene almadenorepvec (AXP000008.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000008.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.